2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-165677
    C22 Galactosylceramide 74645-25-3
    C22 Galactosylceramide is a sphingolipid present in the central nervous system, exhibiting elevated levels in the spinal cord of mice on a methionine-restricted diet, while not affecting the brain or liver; furthermore, it has been identified in the postmortem hippocampus of Alzheimer's disease patients.
    C22 Galactosylceramide
  • HY-16567S
    Asenapine-13C,d3 hydrochloride
    Asenapine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled Asenapine (hydrochloride). Asenapine hydrochloride, an antipsychotic, is a 5-HT (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and Dopamine (D2, D3, D4) receptor antagonist with Ki values of 0.03-4.0 nM for 5-HT and 1.3, 0.42, 1.1 nM for Dopamine receptor, respectively.
    Asenapine-13C,d3 hydrochloride
  • HY-16687B
    Eltoprazine dihydrochloride 143485-51-2
    Eltoprazine (DU 28853) dihydrochloride is a 5-HT1A/5-HT1B receptors agonist and a 5-HT2C receptor antagonist. Eltoprazine dihydrochloride shows antiaggressive and anxiogenic effects.
    Eltoprazine dihydrochloride
  • HY-16688B
    RU 24969 hemisuccinate 66611-27-6
    RU 24969 hemisuccinate is a preferential 5-HT1B agonist, with a Ki of 0.38 nM, but also displays appreciable affinity for the 5-HT1A receptor (Ki=2.5 nM), and has low affinity for other receptor sites in the brain. RU 24969 hemisuccinate could decrease fluid consumption and increase forward locomotion.
    RU 24969 hemisuccinate
  • HY-16728A
    Rapastinel acetate 491872-39-0
    Rapastinel acetate (GLYX-13 acetate) is an N-methyl-D-aspartate (NMDA) receptor modulator with long-acting antidepressant activity. Rapastinel acetate exerts its antidepressant effects by enhancing long-term potentiation (LTP) of synaptic transmission. Rapastinel acetate transiently enhances NMDAR-mediated currents in pyramidal neurons in the hippocampus and medial prefrontal cortex by binding to unique sites on the NMDAR complex. Rapastinel acetate significantly enhanced NMDAR-mediated currents at a concentration of 1 μmol/l and significantly reduced the currents at a concentration of 10 μmol/l. The mechanism of action of Rapastinel acetate is related to the reduction of affinity to intracellular calcium inactivation sites, which provides a theoretical basis for enhancing conductance mediated by NMDAR.
    Rapastinel acetate
  • HY-16748A
    Nelonicline citrate 1026136-84-4
    Nelonicline (ABT-126) citrate is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline citrate is used for the research of shizophrenia and Alzheimer's disease.
    Nelonicline citrate
  • HY-167648
    PD 158771 189152-50-9
    PD 158771 is an antipsychotic agent that functions as a partial agonist for D2 /D3 receptors (Ki = 42.0/13.7 nM) and as an agonist for 5-HT1A receptors (Ki = 2.6 nM). PD 158771 can be utilized in antipsychotic research.
    PD 158771
  • HY-167649
    Poskine 585-14-8
    Poskine is an anticholinergic agent and a central nervous system depressant. Poskine can be utilized in research related to Parkinson's disease and travel sickness .
    Poskine
  • HY-167650
    Fletazepam 34482-99-0
    Fletazepam is a benzodiazepine derivative with sedative, anxiolytic and muscle relaxant effects. Fletazepam can be utilized in neurological research.
    Fletazepam
  • HY-167665
    Fluprazine 76716-60-4
    Fluprazine is an anti-corrosive compound with anxiolytic properties. Fluprazine is used in the study of psychiatric disorders.
    Fluprazine
  • HY-167672
    Propizepine 10321-12-7
    Propizepine is a tricyclic antidepressant compound.
    Propizepine
  • HY-167687
    (RS)-Minesapride 1184662-02-9
    (RS)-Minesapride is a serotonin receptor agonist, exhibiting potential therapeutic activity for patients with irritable bowel syndrome with predominant constipation (IBS-C).
    (RS)-Minesapride
  • HY-167702
    (Rac)-Acetoxyvalerenic acid 81397-67-3
    (Rac)-Acetoxyvalerenic acid is a derivative of valerenic acid that acts as a GABA (A) receptor modulator, potentially providing sedative and sleep-enhancing effects. (Rac)-Acetoxyvalerenic acid exhibits slower permeability across the blood-brain barrier compared to diazepam, indicating that its transport may rely on an unidentified pathway rather than transcellular passive diffusion.
    (Rac)-Acetoxyvalerenic acid
  • HY-167709
    Azacosterol 313-05-3
    Azacosterol (20.25-Diazacholesterol), also known as Diazasterol, acts as a DHCR24 inhibitor and initiates a cascade of reactions in cortical neurons after being administered orally or via intraperitoneal injection.
    Azacosterol
  • HY-16771A
    Valbenazine tosylate 1639208-54-0
    Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM.
    Valbenazine tosylate
  • HY-16771B
    Valbenazine dihydrochloride 1639208-51-7
    Valbenazine (NBI-98854) dihydrochloride is a VMAT2 inhibitor, used to treat tardive dyskinesia. Valbenazine dihydrochloride demonstrates potential benefit in alleviating symptoms associated with movement disorders resulting from chronic dopamine receptor blocking medications. Valbenazine dihydrochloride has been supported by evidence from preclinical models examining its role in the genetic factors linked to tardive dyskinesia.
    Valbenazine dihydrochloride
  • HY-167741
    Chlorisondamine 69-27-2
    Chlorisondamine is a nicotinic antagonist that acts as a ganglionic blocker and has been utilized to evaluate the neurogenic contributions to blood pressure and sympathetic vasomotor tone in animal models. Chlorisondamine has demonstrated antihypertensive properties, primarily being assessed through its effects on blood pressure, cardiac output, and heart rate in various experimental settings, particularly in mice.
    Chlorisondamine
  • HY-167745
    DDR1-IN-9 1934246-20-4
    DDR1-IN-9 is a selective inhibitor of DDR1 with significant kinase activity suppression, exhibiting a Kd value of 4.7 nM and an IC50 value of 9.4 nM. DDR1-IN-9 demonstrates reduced potency against a diverse panel of 400 nonmutated kinases, indicating its specificity. Additionally, DDR1-IN-9 shows favorable pharmacokinetic properties and potential therapeutic effects in a model of pulmonary fibrosis.
    DDR1-IN-9
  • HY-167822
    Caramboxin 1531600-36-8
    Caramboxin is a neurotoxin that can cause acute kidney injury[2].
    Caramboxin
  • HY-167825
    Barakol 24506-68-1
    Barakol is a major compound found in Cassia siamea. Barakol inhibits MMP-3 activity. Barakol potentiates the anti-metastatic effect of Doxorubicin (HY-15142). Barakol induces apoptosis, with ROS generation, increase in expression ratio of Bax/Bcl-2, and caspase-9 activation. Barakol has laxative, anxiolytic, CNS depressant, and antioxidant, anticancer effects.
    Barakol
Cat. No. Product Name / Synonyms Application Reactivity